BLOOD BIOMARKERS TO PREDICT OF THE ONSET AND ADVERSE OUTCOMES OF PREECLAMPSIA: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/5c279x69Keywords:
Biomarkers, blood, pregnancy, preeclampsiaAbstract
Background: Pre-eclampsia is one of the most common pregnancy complications, and a major cause of fetal and maternal morbidity and mortality globally. Diagnosis currently takes place in the third trimester based on clinical symptoms. This systematic review sought to determine the blood biomarkers that are associated with pre-eclampsia, and in particular, the biomarkers that could predict pre-eclampsia in early pregnancy.
Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and MetaAnalysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and SagePub, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.
Result: In the PubMed database, the results of our search brought up 257 articles, whereas the results of our search on SagePub brought up 78 articles. The results of the search conducted for the last year of 2013 yielded a total 198 articles for PubMed and 54 articles for SagePub. In the end, we compiled a total of 5 papers, 4 of which came from PubMed and 1 of which came from SagePub. We included five research that met the criteria.
Conclusion: PlGF and sFlt-1 are the most used in clinical practice, even if their specificity and sensitivity do not justify a default implementation into guidelines to screen all pregnant women. Their role is limited to rule-out a diagnosis of pre-eclampsia in women presenting with symptoms highly suggestive of the disease. Therefore, their current application is not useful for an early prediction of pre-eclampsia. Novel lines of research are needed to identify molecules able to detect pre-eclampsia in a timely manner and which have a predictive value high enough to justify the costs associated with routine measurements in the general pregnant population.
References
Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health [Internet]. 2014 [cited 2023 Dec 5];2(6):323–33. Available from: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(14)70227-X/fulltext
Widmer M, Cuesta C, Khan KS, Conde-Agudelo A, Carroli G, Fusey S, et al. Accuracy of angiogenic biomarkers at ⩽20weeks’ gestation in predicting the risk of pre-eclampsia: A WHO multicentre study. Pregnancy Hypertens. 2015;5(4):330–8.
Magee LA, Nicolaides KH, von Dadelszen P. Preeclampsia. N Engl J Med. 2022;386(19):1817–32.
Fox A, McHugh S, Browne J, Kenny LC, Fitzgerald A, Khashan AS, et al. Estimating the Cost of Preeclampsia in the Healthcare System: Cross-Sectional Study Using Data From SCOPE Study (Screening for Pregnancy End Points). Hypertension. 2017;70(6):1243–9.
Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol. 2018;218(3):287–93.
Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. New England Journal of Medicine. 2017 Aug 17;377(7):613–22.
Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. European Journal of Obstetrics & Gynecology and Reproductive Biology [Internet]. 2013 [cited 2023 Dec 5];170(1):1–7. Available from:
https://www.sciencedirect.com/science/article/abs/pii/S0301211513001966
Yang Y, Le Ray I, Zhu J, Zhang J, Hua J, Reilly M. Preeclampsia Prevalence, Risk Factors, and Pregnancy Outcomes in Sweden and China. JAMA Netw Open. 2021;
Obstet Gynecol. ] Hypertension in pregnancy. Report of the American college of obstetricians and gynecologists’ task force on hypertension in pregnancy. 2013;
Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens [Internet]. 2018 [cited 2023 Dec 5];13:291–310. Available from: https://www.sciencedirect.com/science/article/abs/pii/S2210778918301260
Magley M, Hinson MR. Eclampsia. NCBI Bookshelf. 2023;
Memtsa M, Jurkovic D, Jauniaux ERM. Diagnostic Biomarkers for Predicting Adverse Early Pregnancy Outcomes. BJOG Int J Obstet Gynaecol [Internet]. 2019 [cited 2023 Dec 5]; Available from: https://discovery.ucl.ac.uk/id/eprint/10068533/1/Memtsa_Diagnostic%20Biomarkers%20for%20Predicting%20Adverse%20Early%20Pregnancy%20Outcomes%20Scientific%20Impact.pdf
MacDonald TM, Walker SP, Hannan NJ, Tong S. Clinical tools and biomarkers to predict preeclampsia. The Lancet [Internet]. 2022 [cited 2023 Dec 5];75. Available from: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00574-0/fulltext
Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. New England Journal of Medicine. 2016 Jan 7;374(1):13–22.
Barjaktarovic M, Korevaar TIM, Jaddoe VWV, de Rijke YB, Peeters RP, Steegers EAP. Human chorionic gonadotropin and risk of pre‐eclampsia: prospective population‐based cohort study. Ultrasound Obstet Gynecol [Internet]. 2019 [cited 2023 Dec 5];54(4):477–83. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856821/
Honarjoo M, Kohan S, Zarean E, Tarrahi MJ. Assessment of β-human-derived chorionic gonadotrophic hormone (βhCG) and pregnancy-associated plasma protein A (PAPP-A) levels as predictive factors of preeclampsia in the first trimester among Iranian women: a cohort study. BMC Pregnancy Chilbirth [Internet]. 2019 [cited 2023 Dec 5];19:464. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894335/
Sharma K, Singh R, Kumar M, Gupta U, Rohil V, Bhattacharjee J. First-Trimester Inflammatory Markers for Risk Evaluation of Pregnancy Hypertension. J Obstet Gynaecol India [Internet]. 2018 [cited 2023 Dec 5];68(1):27–32. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783907/
Chen Y, Ou W, Lin D, Lin M, Huang X, Ni S, et al. Increased Uric Acid, Gamma-Glutamyl Transpeptidase and Alkaline Phosphatase in Early-Pregnancy Associated With the Development of Gestational Hypertension and Preeclampsia. Front Cardiovasc Med [Internet]. 2021 [cited 2023 Dec 5]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554001/
Chau K, Hennessy A, Makris A. Placental growth factor and pre-eclampsia. Vol. 31, Journal of Human Hypertension. Nature Publishing Group; 2017. p. 782–6.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
